$MEDP (+44,35%)

Sales: 603M vs 539M expected

Net income: 90M vs 90M expected

EBITDA: 131M vs 117M expected

Book To Bill: 1.03 vs 0.9 prior

Outlook FY 2025

Sales: 2470M vs 2185M expected (the 2470 were not even expected for 2027)

Net Income: 416M vs 390M expected

Absolutely strong numbers. Unfortunately, I didn't dare to buy sooner because it didn't look good

As announced, here's a little update on January today, nothing long, don't want to bore you

Yield

Yield: 6.82% (FTSE All World: 4.23%)

TTWROR: 7.29%

Thus slightly outperformed, hopefully I can extend this lead further

transactions

Sales:

• Shimano $7309 (+0,73%)
• 
  Medpace $MEDP (+44,35%)
• 
  Apple $AAPL (-0,01%)
• 
  Domino's Pizza $DPZ (-1,87%)
• 
  McDonald's $MCD (-1,21%)

Purchases

• Norbit $NORBT (-3,55%) (subsequent purchase)
• Frosta $NLM (+1,61%) (initial purchase)
• RCS Mediagroup $RCS (-1,29%) (initial purchase)
• Uber Technologies $UBER (+0,18%) (initial purchase)
• Sanlorenzo $SL (+1,8%) (initial purchase)
• Charles River Labs $CRL (+2,46%) (subsequent purchase)
• Simply Better Brands $SBBC (-0,09%) (initial purchase)

Looks like a lot of back and forth for now, but with this my portfolio conversion continues and will soon be completed

During my first year of investing, I bought a lot of shares that I didn't really understand what they were doing. In the course of my restructuring, I would like to reduce my number of shares from almost 30 to 15 in the long term. However, I want to do this over a longer period of time, as these are not bad companies.

Shares that I want to sell

Apple $AAPL (-0,01%)
Medpace $MEDP (+44,35%)
ResMed $RMD (+0,63%)
Shimano $7309 (+0,73%)
LVMH $MC (-0,98%)
Genmab $GMAB (-2%)
Pernod Ricard $RI (-0,77%)
Pilbara Minerals $PLS (+6,07%)
Sixt $SIX2 (-4,98%)
McDonald's $MCD (-1,21%)
Domino's Pizza $DPZ (-1,87%)
Crowdstrike $CRWD (+0,75%)
Salesforce $CRM (-0,43%)
Nvidia $NVDA (-1,21%)

Just to clarify, I am not selling these companies because they are bad companies, but because they no longer fit into my investment strategy. I will only invest in companies that are not included in the classic world ETFs, but which I nevertheless understand well.

My question would be what you generally think of this and in which order you would sell the companies listed (as they are listed, this is my preferred order)

$MEDP (+44,35%) Reports Q3 2024

Sales: 533M vs 541M expected (Miss)

EBIT: 112M vs 101M expected (Beat)

Income: 96M vs 90M expected (Beat)

• New Business Awards 533M (Miss) leads to Book-To-Bill of 1.00 down from 1.2-1.3 Range YoY

Outlook for FY24:

Rev: 2.11B vs 2.14B expected (Miss)

EBITDA: 460M vs 450M expected (Beat)

Income: 381M vs 371M expected (Beat)

Expectations were apparently very high. The company is more profitable than expected with less growth. Book-To-Bill is approaching 1. A value below 1 signals a shrinking business, but the backlog is almost 3B, which makes MEDP booked out for a year. So there is still enough time to generate new growth

Hey Community,

$MEDP (+44,35%) is currently correcting

has anyone bought or currently has an opinion

vg

With a tea content of over 50%, I then have

$ELF (-5,5%) and. $MEDP (+44,35%)

sold.

That's called rebalancing 🙈, or maybe not.

Because now it's time to sort out the tech sector and find something new in healthcare.

$MEDP (+44,35%) Were earnings really that bad? Sales are supposed to be lower, but the bottom line has been raised considerably and the backlog has also grown.

Billings have collapsed, which is probably the reason, but I see a good long-term entry point

And there is an immediate follow-up purchase.

After one foot was already in the door.